2052-15-5
CAS 2052-15-5
2052-15-5 (CAS 2052-15-5) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 2052-15-5 used for in pharmaceutical contexts?
2052-15-5 (CAS 2052-15-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 2052-15-5?
No adverse-event association or SIDER side-effect rows are rendered for 2052-15-5 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 2052-15-5 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Butyl Laevulinate with EU status "permitted".
What clinical phase is 2052-15-5 in?
No phase 1-4 clinical development badge is rendered for 2052-15-5 because the matched compound identifier rows do not contain a max-phase value.